Showing results (61-70 of 1,028) with videos related to
Sort By:
Pageof 103
The Lancet. Respiratory Medicine|March 7, 2021
Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trialArvinder S Soin, Kuldeep Kumar, Narendra S Choudhary, et al.The Lancet. Respiratory Medicine|July 14, 2019
Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysisAdam V Benjafield, Najib T Ayas, Peter R Eastwood, et al.The Lancet. Respiratory Medicine|September 24, 2022
Does repeated influenza vaccination attenuate effectiveness? A systematic review and meta-analysisElenor Jones-Gray, Elizabeth J Robinson, Adam J Kucharski, et al.The Lancet. Respiratory Medicine|February 8, 2014
Extracorporeal life support for adults with severe acute respiratory failureLorenzo Del Sorbo, Marcelo Cypel, Eddy FanThe Lancet. Respiratory Medicine|March 27, 2025
Global, regional, and national burden of asthma and atopic dermatitis, 1990-2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021The Lancet. Respiratory Medicine|March 24, 2025
Effectiveness of nasal high-flow oxygen during apnoea on hypoxaemia and intubation success in paediatric emergency and ICU settings: a randomised, controlled, open-label trialShane George, Tara Williams, Susan Humphreys, et al.The Lancet. Respiratory Medicine|December 8, 2024
Augmenting clinical trials in asthma through digital technology, decentralised designs, and person-centric endpoints: opportunities and challengesJob F M van Boven, Richard W Costello, Kit C B Roes, et al.The Lancet. Respiratory Medicine|November 25, 2024
Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohortsJoe G Zein, Nazanin Zounemat-Kerman, Ian M Adcock, et al.The Lancet. Respiratory Medicine|November 1, 2024
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 studyHervé Léna, Laurent Greillier, Claire Cropet, et al.The Lancet. Respiratory Medicine|October 14, 2024
Empirical antibiotic therapy for sepsis: save the anaerobic microbiotaRobert F J Kullberg, Bastiaan W Haak, Rishi Chanderraj, et al.Pageof 103